Koen Andries - Concepedia

Author

Koen Andries

Also Known As

K ANDRIES, K Andries, K. ANDRIES, K. Andries, K. J Andries, K. J. Andries, K.J. Andries, KOEN ANDRIES, Koen Andries, Koen J. Andries

193

Publications

20.2K

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Johnson & Johnson (United States)KU Leuven Janssen (United States)Johnson & Johnson (France)

About

Koen Andries is an author at Janssen (Belgium) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	77	9.5K
2	Natural Sciences	16	16	4.3K
3	Health Sciences	10	10	1.2K
4	Engineering	5	5	209
5	Education	1	1	16

Koen Andries

130

Publications

17.5K

Citations

H-Index

Page 1

	Year	Citations
A Diarylquinoline Drug Active on the ATP Synthase of <i>Mycobacterium tuberculosis</i> Koen Andries, Peter Verhasselt, Jérôme Guillemont, Science World Health OrganizationImmunologyPharmacotherapyAntimicrobial ChemotherapyDrug Resistance	2004	2.1K
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, New England Journal of Medicine	2009	836
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives Rudi Pauwels, Koen Andries, Jan Desmyter, Nature Selective InhibitionMedicinal ChemistryMedicineHuman RetrovirusImmunology	1990	754
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch, New England Journal of Medicine	2014	732
Diarylquinolines target subunit c of mycobacterial ATP synthase Anil Koul, Najoua Dendouga, Karen Vergauwen, Nature Chemical Biology BiosynthesisCellular EnzymologyBiochemistryNatural SciencesMolecular Biology	2007	537
Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants Kalyan Das, Arthur D. Clark, Paul Lewi, Journal of Medicinal Chemistry	2004	511
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline Koen Andries, Cristina Villellas, Nele Coeck, PLoS ONE ImmunologyPharmacotherapyAntibiotic ResistanceDrug ResistanceMycobacterium Tuberculosis	2014	420
Towards a new combination therapy for tuberculosis with next generation benzothiazinones Vadim Makarov, Benoît Lechartier, Ming Zhang, EMBO Molecular Medicine Pulmonary TuberculosisTuberculosis PreventionPharmacologyNew Combination TherapyPharmacological Agent	2014	379
Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance Andreas H. Diacon, Peter R. Donald, Alexander S. Pym, Antimicrobial Agents and Chemotherapy	2012	374
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis Anil Koul, Luc Vranckx, Najoua Dendouga, Journal of Biological Chemistry	2008	360

Page 1